Collegium Pharmaceutical will pay $650 million upfront to acquire ADHD drug Azstarys from Corium Therapeutics. The deal, which includes an additional $135 million in potential milestone payments, gives Collegium a second branded ADHD treatment, Azstarys, along with its Jornay PM.

A new bill introduced in the Maryland House of Delegates requests that pharmas be more specific about the brands related to their otherwise unbranded disease awareness initiatives.

As part of its $15 billion investment commitment in China, AstraZeneca on Thursday unveiled plans to build a commercial cell therapy manufacturing base and an innovation center dedicated to the modality in Shanghai.

Lynavoy is now the first FDA-approved product that can treat cholestatic pruritus in patients with primary biliary cholangitis.

Axplora, a German CDMO that specializes in specialty active pharmaceutical ingredients for small molecules and antibody-drug conjugates, will shell out $60 million to expand its Farmabios manufacturing facility in Gropello Cairoli, Italy.

According to a review by The New York Times, the MFN prices offered on certain drugs through the government’s TrumpRx platform may still be higher than those of other countries.